In the current review, only one case-control study [14] used adjunctive prophylactic systemic amoxicillin/AZM in combination with access flap debridement surgery for the treatment of peri-implantitis and, in addition, assessed biomarkers (IL-1b, MMP-8, MIP-1a), and clinical parameters compared to healthy sites [14]. This evidence concerns the gene IL1B and Peri-Implantitis.